We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Does it work?

5 November 2020 By Robert Cyran

The U.S. biotech group’s market value rocketed on Wednesday after regulators hinted they were persuaded its drug worked. A vote on Friday could send Biogen stock up more. Approval may also signal an easier regulatory touch for desperate diseases. That could help the whole sector.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)